Karyopharm Therapeutics Inc. revenue
Karyopharm Therapeutics Inc.'s revenue was $146m in fiscal 2025, up 0.6% on the year before. Since fiscal 2011 ($152,000) it has grown at a compound 63.3% a year. Over the last twelve months it was $147m.
Revenue history
| Fiscal year | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 30 | 41 | 108 | 210 | 157 | 146 | 145 | 146 | 147 |
| Growth on the year before | — | +317.1% | −39.0% | −40.8% | +9.2% | −38.4% | +942.2% | +>999% | +34.8% | +164.3% | +94.1% | −25.1% | −7.0% | −0.5% | +0.6% | — |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $115M | 78.6% | ▲ 1.8% |
| License and Other | $31.2M | 21.4% | ▼ 3.8% |
From Karyopharm Therapeutics Inc.'s 10-K filed February 13, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Karyopharm Therapeutics Inc. | $147m | 6.8% | 0.1% |
| Beam Therapeutics Inc. | $156m | 158.9% | 24.9% |
| Agenus Inc | $133m | 30.5% | 10.1% |
| Immunitybio, Inc. | $166m | 192.9% | 554.3% |
| Nuvation Bio Inc. | $170m | 1083.6% | — |
| Mesoblast LTD | $120m | 599.2% | — |
Compare with peers
- Beam Therapeutics Inc. revenue
- Agenus Inc revenue
- Immunitybio, Inc. revenue
- Nuvation Bio Inc. revenue
- Mesoblast LTD revenue
Head to head: BEAM vs KPTIAGEN vs KPTIIBRX vs KPTI
More: Biotechnology stocks compared, Health Care sector, rankings of US companies